top of page

Price reduction paves the way for expanded access to highly effective MDR-TB

Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34%. Pretomanid is part of two new treatment regimens with high efficacy and shorter treatment durations recently recommended by the World Health Organization (WHO) as the preferred regimens for most drug-resistant tuberculosis patients. Read more here.

27 views0 comments

Recent Posts

See All


bottom of page